[San Diego, 4th June 2025] – Clearview Market Insights (CVMI) projects that the global aptamers market will grow from USD 1.52 billion in 2024 to USD 4.38 billion by 2031, achieving a compound annual growth rate (CAGR) of 16.3 percent. This strong outlook is supported by accelerating adoption in diagnostics, the rise of nucleic-acid therapeutics, and technological breakthroughs in aptamer discovery and modification.
"Aptamers offer a next-generation alternative to antibodies across diagnostics, therapeutics, and biosensors,” said Dr. Nicole Haider, senior molecular biology analyst at CVMI. “With AI-driven SELEX, nanotechnology convergence, and biosafety-grade modifications, aptamers are stepping into the biotech mainstream."
Request Sample @ https://clearviewmarketinsights.com/report-details/global-aptamers-market/
Key Numbers
- 2024 Market Value: USD 1.52 billion
- 2031 Market Value: USD 4.38 billion
- Seven-Year CAGR: 16.3 percent
- DNA Aptamers Share (2024): 48%
- North America Market Share: 44%
Market Drivers
- Oncology and infectious disease diagnostics
- Chemical versatility and low immunogenicity
- Growth in AI and high-throughput aptamer screening
- Strong research pipelines in targeted delivery and biosensors
Company Highlights
- SomaLogic expanded proteomic applications to over 7,000 protein targets.
- Base Pair Biotechnologies launched AI discovery tools for aptamer affinity profiling.
- Aptamer Group formed alliances with cell therapy developers.
- NeoVentures deployed aptamer-based rapid test kits in food safety and agriculture.
Regional Insights
- North America: Leads in therapeutic R&D and diagnostics adoption.
- Asia-Pacific: Fastest-growing region with rising investment in precision medicine.
- Europe: Focused on academic collaborations and diagnostic biosensor validation.
- LATAM & MEA: Opportunities emerging in food safety and portable diagnostics.
2024–2025 Milestones
Quarter | Event | Outcome |
Q1 2024 | Base Pair debuts AI SELEX tool | Shortens lead identification by 35% |
Q2 2024 | WHO trials aptamer diagnostics for dengue | Positive early results in 3 countries |
Q3 2024 | SomaLogic expands SOMAscan diagnostic use | Validated for cardiac biomarkers |
Q1 2025 | Aptamer Group signs CAR-T targeting partnership | Therapeutic aptamer market entry confirmed |
For more insights, visit https://clearviewmarketinsights.com/
About Clearview Market Insights:
Clearview Market Insights is a leading market research and consulting firm providing in-depth industry analysis and strategic recommendations for businesses worldwide.
Media contact:
Bhavani K
Marketing and Sales Head
ClearView Market Insights
Mail: sales@clearviewmarketinsights.com
Phone: +1 917-993-7369
